Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study mainly observed the ischemic index and vascular leakage index changes on ultra-wide field fluorescence angiography after anti-VEGF treatment , and whether these changes correlated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.
Ultra-wide field fluorescence angiography can clearly observe the peripheral retina. This study mainly observes the ischemic index and vascular leakage index changes on UWFA after anti-VEGF treatment and evaluates these changes associated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| UWFA-RVO-ME | Ultra-wide-field fundus fluorescein angiography on patients with macular edema secondary to retinal vein occlusion treated with Ranibizumab |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS] | Drug | Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in vascular leakage index in different retinal area | Change in vascular leakage index in different retinal area from baseline to 1,2,3,4,6,9 and 12 months | Baseline and 1,2,3,4,6,9 and 12 months |
| Change in non-perfused areas in different retinal area | Change in non-perfused areas in different retinal area from baseline to 1,2,3,4,6,9 and 12 months | Baseline and 1,2,3,4,6,9 and 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in best corrected visual acuity | Change in best corrected visual acuity from baseline to 1,2,3,4,6,9 and 12 months | Baseline and 1,2,3,4,6,9 and 12 months |
| Change in central macular thickness |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Chinese
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| CZ Chen, PHD | Contact | +86 13072765173 | whuchenchzh@163.com |
| Name | Affiliation | Role |
|---|---|---|
| CZ Chen, PHD | Renmin Hospital of Wuhan University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Renmin Hospital of Wuhan University | Recruiting | Wuhan | Hubei | 430060 | China |
Not provided
Not provided
Not provided
Not provided
| Ultra-wide Fluorescein Angiography | Device | Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina |
|
Change in central macular thickness from baseline to1,2,3,4,6,9 and12 months
| Baseline and 1,2,3,4,6,9 and 12 months |
| ID | Term |
|---|---|
| D012170 | Retinal Vein Occlusion |
| D008269 | Macular Edema |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D020246 | Venous Thrombosis |
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D008268 | Macular Degeneration |
| D012162 | Retinal Degeneration |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069579 | Ranibizumab |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided